ZURA icon

Zura Bio

1.19 USD
-0.10
7.75%
At close Apr 1, 4:00 PM EDT
After hours
1.23
+0.04
3.36%
1 day
-7.75%
5 days
-19.59%
1 month
1.71%
3 months
-49.36%
6 months
-69.09%
Year to date
-49.36%
1 year
-58.25%
5 years
-83.56%
10 years
-83.56%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

220% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 10

79% more call options, than puts

Call options by funds: $522K | Put options by funds: $291K

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

10% more funds holding

Funds holding: 78 [Q3] → 86 (+8) [Q4]

7.28% more ownership

Funds ownership: 58.41% [Q3] → 65.69% (+7.28%) [Q4]

29% less capital invested

Capital invested by funds: $151M [Q3] → $107M (-$44M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
740%
upside
Avg. target
$14.67
1,132%
upside
High target
$19
1,497%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Jeff Jones
6% 1-year accuracy
2 / 34 met price target
1,497%upside
$19
Outperform
Maintained
26 Mar 2025
Guggenheim
Yatin Suneja
27% 1-year accuracy
9 / 33 met price target
1,161%upside
$15
Buy
Reiterated
26 Mar 2025
Chardan Capital
Matthew Barcus
0% 1-year accuracy
0 / 2 met price target
740%upside
$10
Buy
Maintained
26 Mar 2025

Financial journalist opinion

Neutral
Business Wire
1 week ago
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. “In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le.
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Neutral
Business Wire
1 month ago
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation.
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Positive
Zacks Investment Research
2 months ago
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
Neutral
Business Wire
3 months ago
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Neutral
Business Wire
4 months ago
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen.
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Neutral
Business Wire
4 months ago
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A.
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Neutral
Business Wire
4 months ago
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. We've worked closely with our contract research organization (CRO) to.
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Neutral
Business Wire
5 months ago
Zura Bio to Participate in Two Upcoming Investor Conferences in November
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET.
Zura Bio to Participate in Two Upcoming Investor Conferences in November
Neutral
Business Wire
6 months ago
Zura Bio to Present at Three Upcoming Investor Conferences in September
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September. Conference Details: Event: H.C. Wainwright 26th Annual Global Investment Conference Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hos.
Zura Bio to Present at Three Upcoming Investor Conferences in September
Neutral
Business Wire
6 months ago
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T.
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
Charts implemented using Lightweight Charts™